SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

HemoDefend-BGA

CTSO·Cytosorbents Corp
NEUTRAL
Drug Impact Rating3/10
Trial phase
Preclinical / Development
Time to market
Not estimable from available sources. The device has not yet entered clinical trials; the most recent DoD contract (October 2022) was for customized filter design and integration into freeze-dried plasma collection systems.
Why 3/10
HemoDefend-BGA is a preclinical/early-stage blood purification filter with no hard, dated catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The most recent public update was a $4.3M DoD contract awarded in October 2022 for development of a freeze-dried universal plasma filter. No clinical trial start, regulatory submission, or decision date has been announced.
Actionable Insight NEUTRAL

HemoDefend-BGA is an early-stage, government-funded development project with no announced clinical trial start or regulatory submission timeline. Watch for any news of a first-in-human study or a new DoD contract milestone. The stock's primary near-term value drivers are the commercial CytoSorb product and the DrugSorb-ATR FDA de novo submission, not HemoDefend-BGA.

Price Chart

Loading chart...

Executive Summary

HemoDefend-BGA is an early-stage blood purification filter being developed by CytoSorbents Corporation (CTSO) with funding from the U.S. Department of Defense. It is designed to remove blood-type antibodies from plasma to create freeze-dried universal plasma for military and civilian trauma use. The program has received cumulative DoD funding of roughly $10M since 2020 across multiple contracts, but no clinical trial has been announced and no regulatory submission date has been set. HemoDefend-BGA is a small, early-stage pipeline program at a company whose primary commercial product is CytoSorb (an approved blood purification filter sold in over 70 countries) and whose main near-term regulatory catalyst is DrugSorb-ATR (which received FDA Breakthrough Device Designation in 2025-2026).

How It Works

HemoDefend-BGA is a filter device that uses proprietary polymer beads to remove blood-type-specific antibodies (anti-A and anti-B) from donated blood plasma. The goal is to convert any blood-type plasma into "universal" plasma that can be given to any patient regardless of blood type, and then freeze-dry it for long-term storage and battlefield use.

Trial Status

HemoDefend-BGA has been funded through multiple U.S. Department of Defense contracts since 2020 (a $2.9M Phase III STTR contract in June 2020, a $1.1M contract in October 2020, a ~$2.0M contract in September 2022, and a ~$4.3M contract in October 2022). These contracts support development of a filter that removes blood-type-specific antibodies from plasma to create freeze-dried universal plasma. No clinical trial records were found in the SecBot biotech pipeline or FDA data tools, and no public update on clinical trial initiation was identified in web searches.

The Two-Sided Case

▲ Bull Case3
The U.S. Department of Defense has awarded cumulative contracts of roughly $10M for HemoDefend-BGA development, signaling military interest in universal freeze-dried plasma for battlefield trauma care.
The technology leverages CytoSorbents' proprietary polymer adsorption platform, which is already commercialized in the CytoSorb product.
If successful, a freeze-dried universal plasma product could address a significant military and civilian medical need for a shelf-stable, blood-type-independent plasma product.
▼ Bear Case4
HemoDefend-BGA remains in preclinical/development stage with no announced clinical trial start or regulatory submission timeline, years after the initial government contracts were awarded.
The program is a small part of CytoSorbents' pipeline; the company's primary focus and value drivers are the commercial CytoSorb product and the DrugSorb-ATR FDA de novo submission.
CytoSorbents has limited financial resources (Q3 2026 revenue of $9.7M, recent Nasdaq compliance challenges, and a market cap that required a reverse stock split in September 2026), which may constrain development timelines for early-stage programs.
No public data on the filter's efficacy in removing blood-type antibodies or safety in human transfusion has been identified.

Upcoming Catalysts

  • No hard-dated catalysts identified for HemoDefend-BGA specifically. The broader company catalysts include the DrugSorb-ATR FDA de novo submission status and potential Nasdaq MVLS compliance deadline of December 28, 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Cytosorbents Corp PRESS-RELEASE CTSO ·Originating report

Sources · 7

Hover a chip for the title
1 prnewswire.com2 markets.businessinsider.com3 fox4kc.com4 prnewswire.com5 prnewswire.com6 nasdaq.com7 br.advfn.com